Your browser doesn't support javascript.
loading
Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
Wang, Jitao; Hou, Zhiyun; Liu, Jianxin; Gu, Ye; Wu, Yunhong; Chen, Zhenhuai; Ji, Jiansong; Diao, Shiqi; Qiu, Yuanwang; Zou, Shengqiang; Zhang, Aiguo; Zhang, Nina; Wang, Fengxian; Li, Xue; Wang, Yan; Liu, Xing; Lv, Cheng; Chen, Shubo; Liu, Dengxiang; Ji, Xiaolin; Liu, Chao; Ren, Tao; Sun, Jingwei; Zhao, Zhongwei; Wu, Fazong; Li, Fenxiang; Wang, Ruixu; Yan, Yan; Zhang, Shiliang; Ge, Guohong; Shao, Jiangbo; Yang, Shiying; Liu, Chuan; Huang, Yifei; Xu, Dan; Li, Xiaoguo; Ai, Jingwen; He, Qing; Zheng, Ming-Hua; Zhang, Liting; Xie, Qing; Rockey, Don C; Fallowfield, Jonathan A; Zhang, Wenhong; Qi, Xiaolong.
  • Wang J; CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China; CHESS-COVID-19 Group, Jincheng People's Hospital, Jincheng, China; CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, China.
  • Hou Z; CHESS-COVID-19 Group, Jincheng People's Hospital, Jincheng, China.
  • Liu J; CHESS-COVID-19 Group, Jinzhou Central Hospital, Jinzhou, China.
  • Gu Y; CHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang City, Shenyang China.
  • Wu Y; CHESS-COVID-19 Group, Hospital of Chengdu Office, People's Government of Tibet Autonomous Region, Chengdu, China.
  • Chen Z; CHESS-COVID-19 Group, Baoding People's Hospital, Baoding, China.
  • Ji J; CHESS-COVID-19 Group, Lishui Central Hospital, Lishui, China.
  • Diao S; CHESS-COVID-19 Group, The Third People's Hospital of Linfen City, Linfen, China.
  • Qiu Y; CHESS-COVID-19 Group, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China.
  • Zou S; CHESS-COVID-19 Group, The Third People's Hospital of Zhenjiang City, Zhenjiang, China.
  • Zhang A; CHESS-COVID-19 Group, Jincheng People's Hospital, Jincheng, China.
  • Zhang N; CHESS-COVID-19 Group, Jincheng People's Hospital, Jincheng, China.
  • Wang F; CHESS-COVID-19 Group, Jinzhou Central Hospital, Jinzhou, China.
  • Li X; CHESS-COVID-19 Group, Jinzhou Central Hospital, Jinzhou, China.
  • Wang Y; CHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang City, Shenyang China.
  • Liu X; CHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang City, Shenyang China.
  • Lv C; CHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang City, Shenyang China.
  • Chen S; CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, China.
  • Liu D; CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, China.
  • Ji X; CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, China.
  • Liu C; CHESS-COVID-19 Group, Hospital of Chengdu Office, People's Government of Tibet Autonomous Region, Chengdu, China.
  • Ren T; CHESS-COVID-19 Group, Hospital of Chengdu Office, People's Government of Tibet Autonomous Region, Chengdu, China.
  • Sun J; CHESS-COVID-19 Group, Baoding People's Hospital, Baoding, China.
  • Zhao Z; CHESS-COVID-19 Group, Lishui Central Hospital, Lishui, China.
  • Wu F; CHESS-COVID-19 Group, Lishui Central Hospital, Lishui, China.
  • Li F; CHESS-COVID-19 Group, The Third People's Hospital of Linfen City, Linfen, China.
  • Wang R; CHESS-COVID-19 Group, The Third People's Hospital of Linfen City, Linfen, China.
  • Yan Y; CHESS-COVID-19 Group, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China.
  • Zhang S; CHESS-COVID-19 Group, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China.
  • Ge G; CHESS-COVID-19 Group, The Third People's Hospital of Zhenjiang City, Zhenjiang, China.
  • Shao J; CHESS-COVID-19 Group, The Third People's Hospital of Zhenjiang City, Zhenjiang, China.
  • Yang S; Department of Hepatology, The First Hospital of Lanzhou University, Lanzhou, China.
  • Liu C; CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
  • Huang Y; CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
  • Xu D; CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
  • Li X; CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
  • Ai J; Department of Infectious Disease, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
  • He Q; National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, Shenzhen, China.
  • Zheng MH; NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Zhang L; Department of Hepatology, The First Hospital of Lanzhou University, Lanzhou, China.
  • Xie Q; Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Rockey DC; Digestive Disease Research Center, Medical University South Carolina, Charleston, South Carolina, USA.
  • Fallowfield JA; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
  • Zhang W; Department of Infectious Disease, Huashan Hospital Affiliated to Fudan University, Shanghai, China. Electronic address: zhangwenhong@fudan.edu.cn.
  • Qi X; CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China. Electronic address: qixiaolong@vip.163.com.
J Hepatol ; 75(2): 439-441, 2021 08.
Article en En | MEDLINE | ID: mdl-33905793
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas de Productos Inactivados / Vacunación / Anticuerpos Neutralizantes / Enfermedad del Hígado Graso no Alcohólico / Inmunogenicidad Vacunal / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adult / Female / Humans / Male País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas de Productos Inactivados / Vacunación / Anticuerpos Neutralizantes / Enfermedad del Hígado Graso no Alcohólico / Inmunogenicidad Vacunal / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adult / Female / Humans / Male País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article